Aurora Kinases: New Targets for Cancer Therapy

Richard D. Carvajal(Memorial Sloan Kettering Cancer Center), Gary K. Schwartz(Cornell University)

Clinical Cancer Research

December 1, 2006

10.1158/1078-0432.ccr-06-1405

Cited by 274

Related Papers

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

|Journal of Clinical Oncology|2009|573

Uveal melanoma: epidemiology, etiology, and treatment of primary disease

|Clinical ophthalmology|2017|402

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

|Oncotarget|2015|112

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

|PLoS ONE|2012|77

90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1

|Molecular Pharmacology|2008|44